NCT04695860View on ClinicalTrials.gov

Anti-FGF23 (Burosumab) in Adult Patients With XLH

PHASE3CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions

X-linked Hypophosphatemia

Interventions

DRUG

Burosumab

Q4w, 1mg/kg Body weight, s.c.

Trial Locations (1)

97074

Clinical Trial Unit, Orthopedic Department, Wuerzburg University, Würzburg

Sponsors

Collaborators (1)

Kyowa Kirin, Inc.

All Listed Sponsors

collaborator

Kyowa Kirin, Inc.

INDUSTRY

lead

Wuerzburg University Hospital

OTHER